Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XCY0 | ISIN: US90400D1081 | Ticker-Symbol: UP0
Tradegate
03.06.25 | 08:03
31,400 Euro
-3,09 % -1,000
1-Jahres-Chart
ULTRAGENYX PHARMACEUTICAL INC Chart 1 Jahr
5-Tage-Chart
ULTRAGENYX PHARMACEUTICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
32,20032,80017:34
32,20032,80017:28

Aktuelle News zur ULTRAGENYX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.05.What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical2
28.05.Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 20284
20.05.Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)64NOVATO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
► Artikel lesen
19.05.Ultragenyx Pharmaceutical Inc. - 8-K, Current Report1
14.05.Ultragenyx Pharmaceutical Inc.: Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report252NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility....
► Artikel lesen
07.05.Ultragenyx projects $640M-$670M revenue for 2025 with strong product growth14
06.05.Ultragenyx Pharmaceutical Inc. - 8-K, Current Report-
06.05.Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update44First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million...
► Artikel lesen
ULTRAGENYX Aktie jetzt für 0€ handeln
06.05.Ultragenyx Pharmaceutical GAAP EPS of -$1.57 beats by $0.08, revenue of $139M misses by $5.46M2
05.05.Ultragenyx Pharmaceutical Q1 2025 Earnings Preview2
22.04.Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)57NOVATO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
► Artikel lesen
29.03.Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy19
27.03.Ultragenyx Is Uniquely Positioned In Long Term, Remains On JPMorgan's Focus List15
19.03.Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)86NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
► Artikel lesen
19.03.Ultragenyx, Mereo shares rise following OIF call insights4
17.03.Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews4
17.03.Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight12
26.02.Cantor Fitzgerald maintains $118 target on Ultragenyx stock1
19.02.Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)98NOVATO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
► Artikel lesen
19.02.Ultragenyx Pharmaceutical Inc. - 10-K, Annual Report-
Weiter >>
65 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1